Aditxt, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ADTX research report →
Range $1280 – $1280
Price Chart
About the company
Aditxt, Inc. is a biotechnology firm dedicated to advancing immune system health through innovative mapping and reprogramming techniques. The company's developments include AditxtScore, a platform designed to empower individuals by providing insights into their immune profiles for better management and informed awareness of immune system attacks or dysfunctions.
- CEO
- Jeffrey Busch
- IPO
- 2020
- Employees
- 26
- HQ
- Mountain View, CA, US
Get TickerSpark's AI analysis on ADTX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $2.99M
- P/E
- -0.00
- PEG
- 0.00
- P/S
- 208.84
- P/B
- -0.00
- EV/EBITDA
- -0.14
- Div Yield
- 0.00%
- Gross Margin
- 19.89%
- Op Margin
- -127821.37%
- Net Margin
- -362385.72%
- ROE
- 926.02%
- ROIC
- -406.31%
Latest fiscal year · YoY change
- Revenue
- $3.19K-97.6%
- Gross Profit
- $268+100.1%
- Op Income
- $-19,570,724
- Net Income
- $-41,714,201-21.1%
- EPS
- $-1153.83+62.3%
- OCF Growth
- -153152.4%
- FCF Growth
- -153234.4%
- 52W High
- $18232.78
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $52.68
- Beta
- 0.93
- RSI (14)
- 20
- Avg Volume
- 25.42M
No earnings-call transcripts are available for ADTX yet.
- Free Float
- 0.0%
- Shares Outstanding
- 997.98M
- Float Shares
- 341.76K
of shares held by institutions
25 13F filers
Buy/sell ratio 0.85. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 23, 26 | Takeover Time 2026 LLC | sell | 3,420,439 |
| Jun 18, 26 | HRT FINANCIAL LP | buy | 7,340,178 |
| Jun 22, 26 | HRT FINANCIAL LP | sell | 5,120,480 |
| Jun 18, 26 | HRT FINANCIAL LP | other | 0 |
| Jun 22, 26 | Tai Wey Ann | other | 0 |
| Jun 16, 26 | Tai Wey Ann | other | 0 |
| Jun 12, 26 | Takeover Time 2026 LLC | other | 0 |
| Jun 16, 26 | HRT FINANCIAL LP | sell | 3,132,480 |
| Jun 17, 26 | DRW Securities, LLC | sell | 126,772 |
| Jun 15, 26 | HRT FINANCIAL LP | buy | 2,114,344 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ADTX coverage
Recent articles, reports, and earnings notes.
No research on ADTX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ADTX report →Aditxt Signed Definitive Agreement Valuing Ignite Proteomics at Approximately $150 Million
businesswire.com · Jun 9
Ignite Proteomics Announces Prospective 10,000-Patient Oncology Registry to Evaluate Functional Proteomics in Cancer Therapy Selection
businesswire.com · Jun 8
Aditxt, Inc. Appoints Jeffrey M. Busch as Interim Chief Executive Officer; Founder and Former CEO of $1B NYSE Enterprise Which Delivered ~8.5% Dividends to Shareholders
businesswire.com · Jun 1
Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-27 Reverse Stock Split Effective at the Open of Trading on May 18, 2026
businesswire.com · May 14
Dana-Farber Cancer Institute Study Demonstrates Predictive Value of Ignite Proteomics' RPPA Platform for T-DXd (Enhertu®) Therapy in Metastatic Breast Cancer Patients
businesswire.com · Apr 20
Aditxt, Inc. (NASDAQ:ADTX) Sees Significant Drop in Short Interest
defenseworld.net · Mar 28
Aditxt Subsidiary Ignite Proteomics Appoints Public Company Veteran Jeff Busch as Chief Executive Officer
businesswire.com · Mar 19
Aditxt Acquires Ignite Proteomics to Address a Critical Challenge in Cancer Care: Optimizing Therapy Selection
businesswire.com · Mar 13
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.